145 related articles for article (PubMed ID: 36200383)
21. Zinc-α2-glycoprotein as an inhibitor of amine oxidase copper-containing 3.
Romauch M
Open Biol; 2020 Apr; 10(4):190035. PubMed ID: 32315567
[TBL] [Abstract][Full Text] [Related]
22. Siglec-9 is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer.
Aalto K; Autio A; Kiss EA; Elima K; Nymalm Y; Veres TZ; Marttila-Ichihara F; Elovaara H; Saanijoki T; Crocker PR; Maksimow M; Bligt E; Salminen TA; Salmi M; Roivainen A; Jalkanen S
Blood; 2011 Sep; 118(13):3725-33. PubMed ID: 21821708
[TBL] [Abstract][Full Text] [Related]
23. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 deficiency reduces leukocyte infiltration into adipose tissue and favors fat deposition.
Bour S; Caspar-Bauguil S; Iffiú-Soltész Z; Nibbelink M; Cousin B; Miiluniemi M; Salmi M; Stolen C; Jalkanen S; Casteilla L; Pénicaud L; Valet P; Carpéné C
Am J Pathol; 2009 Mar; 174(3):1075-83. PubMed ID: 19218346
[TBL] [Abstract][Full Text] [Related]
24. Physiological and pathological implications of semicarbazide-sensitive amine oxidase.
Yu PH; Wright S; Fan EH; Lun ZR; Gubisne-Harberle D
Biochim Biophys Acta; 2003 Apr; 1647(1-2):193-9. PubMed ID: 12686132
[TBL] [Abstract][Full Text] [Related]
25. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications.
Stolen CM; Madanat R; Marti L; Kari S; Yegutkin GG; Sariola H; Zorzano A; Jalkanen S
FASEB J; 2004 Apr; 18(6):702-4. PubMed ID: 14977883
[TBL] [Abstract][Full Text] [Related]
26. Increased primary amine oxidase expression and activity in white adipose tissue of obese and diabetic db-/- mice.
Iffiú-Soltész Z; Mercader J; Daviaud D; Boucher J; Carpéné C
J Neural Transm (Vienna); 2011 Jul; 118(7):1071-7. PubMed ID: 21298297
[TBL] [Abstract][Full Text] [Related]
27. A peptide inhibitor of vascular adhesion protein-1 (VAP-1) blocks leukocyte-endothelium interactions under shear stress.
Yegutkin GG; Salminen T; Koskinen K; Kurtis C; McPherson MJ; Jalkanen S; Salmi M
Eur J Immunol; 2004 Aug; 34(8):2276-85. PubMed ID: 15259025
[TBL] [Abstract][Full Text] [Related]
28. VAP-1, a novel molecule linked to endothelial damage and kidney function in kidney allograft recipients.
Koc-Zorawska E; Malyszko J; Malyszko JS; Mysliwiec M
Kidney Blood Press Res; 2012; 36(1):242-7. PubMed ID: 23154672
[TBL] [Abstract][Full Text] [Related]
29. Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation.
Salmi M; Jalkanen S
Antioxid Redox Signal; 2019 Jan; 30(3):314-332. PubMed ID: 29065711
[No Abstract] [Full Text] [Related]
30. Leukocyte trafficking-associated vascular adhesion protein 1 is expressed and functionally active in atherosclerotic plaques.
Silvola JM; Virtanen H; Siitonen R; Hellberg S; Liljenbäck H; Metsälä O; Ståhle M; Saanijoki T; Käkelä M; Hakovirta H; Ylä-Herttuala S; Saukko P; Jauhiainen M; Veres TZ; Jalkanen S; Knuuti J; Saraste A; Roivainen A
Sci Rep; 2016 Oct; 6():35089. PubMed ID: 27731409
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical study of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 in the hippocampal vasculature: pathological synergy of Alzheimer's disease and diabetes mellitus.
Valente T; Gella A; Solé M; Durany N; Unzeta M
J Neurosci Res; 2012 Oct; 90(10):1989-96. PubMed ID: 22714978
[TBL] [Abstract][Full Text] [Related]
32. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases.
Kurkijärvi R; Adams DH; Leino R; Möttönen T; Jalkanen S; Salmi M
J Immunol; 1998 Aug; 161(3):1549-57. PubMed ID: 9686623
[TBL] [Abstract][Full Text] [Related]
33. Proteolytic cleavage of vascular adhesion protein-1 induced by vascular endothelial growth factor in retinal capillary endothelial cells.
Yoshida S; Murata M; Noda K; Matsuda T; Saito M; Saito W; Kanda A; Ishida S
Jpn J Ophthalmol; 2018 Mar; 62(2):256-264. PubMed ID: 29392528
[TBL] [Abstract][Full Text] [Related]
34. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey.
Dunkel P; Balogh B; Meleddu R; Maccioni E; Gyires K; Mátyus P
Expert Opin Ther Pat; 2011 Sep; 21(9):1453-71. PubMed ID: 21675926
[TBL] [Abstract][Full Text] [Related]
35. Vascular adhesion protein-1 and microvascular diabetic complications.
Singh AD; Kulkarni YA
Pharmacol Rep; 2022 Feb; 74(1):40-46. PubMed ID: 35001320
[TBL] [Abstract][Full Text] [Related]
36. Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration.
Schilter HC; Collison A; Russo RC; Foot JS; Yow TT; Vieira AT; Tavares LD; Mattes J; Teixeira MM; Jarolimek W
Respir Res; 2015 Mar; 16(1):42. PubMed ID: 25889951
[TBL] [Abstract][Full Text] [Related]
37. Mapping the interaction site and effect of the Siglec-9 inflammatory biomarker on human primary amine oxidase.
Lopes de Carvalho L; Elovaara H; de Ruyck J; Vergoten G; Jalkanen S; Guédez G; Salminen TA
Sci Rep; 2018 Feb; 8(1):2086. PubMed ID: 29391504
[TBL] [Abstract][Full Text] [Related]
38. Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target.
Dunkel P; Gelain A; Barlocco D; Haider N; Gyires K; Sperlágh B; Magyar K; Maccioni E; Fadda A; Mátyus P
Curr Med Chem; 2008; 15(18):1827-39. PubMed ID: 18691041
[TBL] [Abstract][Full Text] [Related]
39. Functional modulation of vascular adhesion protein-1 by a novel splice variant.
Kaitaniemi S; Grön K; Elovaara H; Salmi M; Jalkanen S; Elima K
PLoS One; 2013; 8(1):e54151. PubMed ID: 23349812
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of the multitarget compound DPH-4 on human SSAO/VAP-1-expressing hCMEC/D3 cells under oxygen-glucose deprivation conditions: an in vitro experimental model of cerebral ischaemia.
Sun P; Esteban G; Inokuchi T; Marco-Contelles J; Weksler BB; Romero IA; Couraud PO; Unzeta M; Solé M
Br J Pharmacol; 2015 Nov; 172(22):5390-402. PubMed ID: 26362823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
